METABOLIC SYNDROME DONALD FELIT TO, M.D.
|
|
- Maria Holland
- 7 years ago
- Views:
Transcription
1 METABOLIC SYNDROME DONALD FELITTO, M.D.
2 DEFINITIONS
3 WHO Definition 1999 Diabetes or impaired fasting glycemia or IGT or insulin resistance Plus any two: Obesity: BMI > 30, WTH ratio>0.9 male or >0.85 female. Dyslipidemia: TG >or= 1.7mmol/liter or HDL cholesterol <0.9 mmol/l male or <1.0mmol/l female. Hypertension: BP > 140/90 mmhg Microalbuminuria: albumin excretion >20mcg/min
4 European Group for the Study of Insulin Resistance 1999 Insulin Resistance: hyperinsulinemia: top 25% of the fasting insulin values from the non-diabetic population. Plus 2 or more of the following: Central obesity: waist circumference > or = to 94 cm for male and 84 cm female Dyslipidemia: TG > 2.0mmol/L or HDL cholesterol > 1.0mmol/L Hypertension: BP 140/90 and/or medication Fasting plasma glucose > 6.1mmol/l
5 National Cholesterol Education Program s Adult Treatment Panel III (2001) Three or more of the following: Central Obesity: waist > 40 in. male and waist > 34 in. female. TG > or = to 150 Low HDL cholesterol: < 40 male and less than 50 female. Hypertension: BP > or = 135/85mm/Hg Fasting plasma glucose > 110
6 American Association of Endocrinology - Statement Insulin Resistance Syndrome (2002) Four Identifying Abnormalities: High Triglycerides Low HDL cholesterol Hypertension Elevated fasting or post load (75g) glucose. OBESITY is not a component of the definition.
7 WHO 1999 ATP III 2001 Am. Assoc. of Endo 2002 International Diabetes Federation 2005 Comparison of Definitions Risk Factor Impaired glucose regulation (+2 other risks,) IR, IGT, DM Central Obesity BP > 140/90 TG >150 or HDL. M <35, F <39 Mcroalbuminuria Risk Factor (any 3 of 5 risk factors) Blood Sugar >/= 100 Central obesity BPS >/=130, BPD >/= 85 Triglyceride >/= 150 HDL <40M, <50F Risk factor Elevated fasting or post load (75g) glucose Hypertension Elevated Triglycerides Low HDL (no mention of obesity) Risk Factor Central Obesity (plus >/= 2 factors) BS>/=100 or DM BPS>/=135, BPD >/=85 TG > 150 HDL <40M,,50F
8
9 Table 2: AHA/NHLBI criteria for diagnosis of metabolic syndrome
10 Commonalities A large waistline: Central Obesity/ Visceral Obesity For women a waistline > 35 and for men >40 Dyslipidemia: High Triglyceride and low HDL in the blood Hypertension: 135/85 or 140/90 Some form of insulin resistance
11 Case Report Mr. B. is a 63 year old man with a past medical history for Hypertension, Dyslipidemia, Obesity and family history of Type 2 Diabetes Mellitus was evaluated for weight loss. The BMI was 36 kg/m2, BP was 144/84, fasting blood sugar was 125, TC was 183, LDL cholesterol 112, TG 171, HDL cholesterol 37. The EKG showed old MI.
12 Prevalence of Metabolic Syndrome USA Native Americans 45-49y/o: (58% women and 45% men) USA Filipina-Americans: 50-69y/o (35%) USA 30-79y/o: 25+% (>60y/o 40+%) USA non-hispanic white:30-79y/o (25%) USA Mexican American 30-79y/o (30%)
13 Prevalence of Metabolic Syndrome Weiss et al. (2004) Severely obese children/adolescents, the prevalence is 50%! NHANES III 12-19y/o using ATPIII criteria for metabolic syndrome the prevalence is 4.2%.
14 Risk factors for developing Metabolic Syndrome Overweight Obesity Lack of physical activity (sedentary lifestyle) Insulin resistance Genetics Older age NHLBI 2007
15 Conditions that may play a role Fatty Liver (NASH) Polycystic Ovarian Syndrome Gallstones Sleep Apnea NHLBI 2007
16 The diagnosis of metabolic syndrome requires a tape measure or accurate eye; fasting lipogram and plasma glucose measurements; and BP measurements. Opie L H Circulation. 2007;115:e32-e35 Copyright American Heart Association, Inc. All rights reserved.
17 Mechanisms Abdominal adipose tissue is an endocrine organ which releases into circulation FFA, Angiotensin II and adipokines. Increased FFA in the blood inhibit uptake of glucose by muscle. Excess FFA and AT II damage the pancreas. The pancreas makes extra insulin, it is an insufficient to counter hyperglycemia So, there is increased insulin levels and increased glucose. This is insulin resistance. AT II increases BP through vasoconstriction. Inflammatory cytokines are responsible IR and Hypertension Hyperglycemia and increased circulating FFA contribute to increased manufacture of TG by the liver. Circulating TG increase so that lipoproteins carry more TG and less HDL. Circulation 2007;115:e32-e35
18 Mechanisms Insulin resistance: Increased postprandial insulin to maintain euglycemia. Increased fasting insulin secretion to maintain euglycemia. Eventually, hyperglycemia in many. Hyperglycemia and increased FFA will increase insulin levels further. Beta cell dysfunction, defective insulin secretion
19 Pathophysiology AT II increases Blood Pressure The adipose tissue liberates Tumor Necrosis Factor alpha and interleukins that provoke an inflammatory reaction which promotes insulin resistance and promotes and promotes hypertension. Hyperglycemia and elevated levels of circulating FFA foster the manufacture of triglycerides by the liver. Lipoproteins carry triglyceride and TG level rises. HDL molecules are small and they are easily secreted. These physiologic reactions cause the high TG: HDL lipid abnormality. Opie L H Circulation. 2007;115:e32-e35
20 Inflamation Inflammation associated with Insulin resistance: IL 6, TNF a, CRP, are increased. IL 6 and other cytokines increase hepatic glucose production, inc. hepatic production of VLDL and increase insulin resistance in muscle tissue. Cytokines plus FFA increase fibrinogen and plasminogen activator inhibitor 1 (from the liver) promote a prothrombotic state.
21 Adiponectin Adiponectin: Anti-inflammatory cytokine produced by adipose tissue. Enhances insulin sensitivity and inhibits the inflammatory process. Inhibits hepatic glucose production. Enhances glucose transport to muscle. It is reduced with insulin resistance. Some associate low concentrations with progression of subclinical CAD and MI.
22 The diagnosis of metabolic syndrome requires a tape measure or accurate eye; fasting lipogram and plasma glucose measurements; and BP measurements. Opie L H Circulation. 2007;115:e32-e35 Copyright American Heart Association, Inc. All rights reserved.
23
24 Manifestations Obesity and Physical Inactivity Dyslipidemia Insulin Resistance/IGT/Hyperinsulinemia (Na retention, SNS stimulation, HTN, increased circulating FFA). Prothrombotic state Pro-inflammatory state Hyperuricemia defects in insulin action on the renal tubular reabsorption of uric acid. Asymmetric dimethylarginine (endothelial dysfunction) Homocysteinemia Microalbuminuria Non-alcoholic fatty liver OSA? Leptin deficiency/dysfunction (TG accumulation and?hyperinsulinism) NHLBI 2007
25 Diagnosis of Metabolic Syndrome Large waistline High TG and low HDL (3:1) Blood Pressure >130/85 High FBS About 85% of people with Type 2 Diabetes Mellitus have Metabolic Syndrome NHLBI 2007
26 Case Report A 45 year old man with a PHx significant for MCD, Obesity, Hyperlipidemia, HTN who despite counseling developed Type 2 DM. BP controlled with ACEI. Total cholesterol 303, TG 1498, Abnormal LFT s, TC/HDL cholesterol 9.2
27 A patient is found to have Metabolic Syndrome; so what?
28 Metabolic Syndrome Lifestyle High Sodium Intake High Caloric Intake Atherogenic diet Carbohydrate abuse Sedentary living plus Predisposition Tobacco Abuse Obesity Hypertension Hyperlipidemia Insulin Resistance Premature Coronary Heart Disease Metabolic Syndrome Type 2 Diabetes Mellitus Neuropathy Nephropathy Retinopathy Vasculopathy
29 Metabolic Syndrome is associated with risk of cardiovascular disease The risk of vascular complications (CHD, Type 2 Diabetes Mellitus and Stroke) increase with the number of risk factors. People with Metabolic Syndrome are twice as likely to develop CHD and 5 times as likely to develop Type 2 Diabetes Mellitus when compared to patients who do not have Metabolic Syndrome. Coagulopathy (propensity for blood clotting) and inflammation (elevated C-Reactive Protein) The risk must be added to finding of high LDL and smoking NHLBI 2007
30 Risk of Metabolic Syndrome Although the metabolic syndrome unequivocally predisposes to type 2 diabetes mellitus, 48,58 62 many investigators of cardiovascular diseases consider this syndrome to be a multidimensional risk factor for ASCVD. 1,58 Several recent reports show that the metabolic syndrome is associated with greater risk for cardiovascular disease, but once type 2 diabetes mellitus emerges, cardiovascular risk increases even more. Ann Intern Med. doi: /m
31 Metabolic Syndrome-Risk Other metabolic risk factors likewise appear individually to be: atherogenic diet Hypertension Elevated blood glucose prothrombotic state proinflammatory state. Indeed, 3 of the metabolic risk factors elevated apob-containing lipoproteins, 1 low HDL-C levels, 1 and hypertension 91 are well established, major risk factors. Each imparts increased risk even when only marginally abnormal. Ann Intern Med. doi: /m
32 THERAPY
33 Treatments Healthy Lifestyle Eating a healthy diet/losing weight Increasing physical activity Quitting the cigarette smoking habit
34 The Diabetes Prevention Program A randomized clinical trial testing strategies to prevent Type 2 Diabetes Mellitus. High risk individuals with elevated fasting glucose and impaired glucose tolerance. 3,234 participants 27 centers in the U.S.- 20% of whom were over 65y/o. Mean age 51y/o, BMI 34m/kg2. Three interventions: intensive lifestyle intervention, Metformin, Placebo.
35 Diabetes Prevention Program Primary outcome was development of Type 2 DM Secondary outcomes: CVD, changes in glycemia, Beta cell function, insulin sensitivity, obesity, diet, physical activity, health related QOL, occurrence of adverse events.
36 Diabetes Prevention Program Inclusion Criteria: Age greater than or equal to 25y/o. BMI >/= 24kg/m2. IGT 2h plasma glucose Elevated FPG (95-125mg/dl)
37 Diabetes Prevention Program ILS reduced the incidence of Type 2 DM by 58%. Metformin reduced the incidence of Type 2 DM by 31% over 2.8 years. 6.9 participants with IGT would need to be treated with ILS for 3 years to prevent one case of Type 2 DM. For Metformin 14.3 participants for 3 yrs to prevent one case Type 2 DM. Cost analysis shows both therapies to be cost effective. Diabetes Care 9/03
38 Lifestyle changes Losing weight Reduce salt in the diet DASH diet (Dietary Approaches to Stop Hypertension) Increase activity/fitness
39
40 Therapy: Finnish Study Study design: Reduce fat intake Reduce saturated fat Increase Fiber Increase exercise Yield was a 60% reduction of Type II Diabetes. Finnish Diabetes Prevention Study Group. Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.tuomilehto et al. N Engl J Med. 2001;344:
41 Treatment of Metabolic Syndrome Therapeutic Strategies: 1. Lifestyle changes, exercise, adherence to the Mediterranean diet, and weight loss less new diabetes 2. Metformin (less new diabetes, not as good as lifestyle changes) 3. Glitazones, for non-diabetics with high cardiovascular risk: reduce fatty free acids, reduce insulin resistance, Increase HDL, must balance these against possible weight gain and heart failure 4. Choice of antihypertensives: -blocker/diuretic much more likely to cause metabolic syndrome than calcium channel blockers/angiotensinconverting enzyme inhibitors32 Opie L H Circulation. 2007;115:e32-e35
42 BEHAVIORAL COUNSELING TO PROMOTE A HEALTHFUL DIET AND PHYSICAL ACTIVITY FOR CARDIOVASCULAR DISEASE PREVENTION IN ADULTS WITH CARDIOVASCULAR RISK FACTORS CLINICAL SUMMARY OF U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATION Ann Intern Med. doi: /m
43 Importance of the Recommendations 1. Obesity is associated with increased CVD mortality 2. Adults who adhere to national guidelines for a healthy diet and physical activity have a lower cardiovascular morbidity and mortality than those who do not 3. All persons, regardless of CVD risk status, can accrue the health of improved nutrition, healthy eating behaviors and increased physical activity. AnnInternMed.doi: /M
44 Proof of Efficacy The task force found adequate evidence that intensive behavioral counseling interventions have moderate benefits for CVD risk in overweight or obese adults who are at increased risk for CVD, including: Decreases in blood pressure, lipid and fasting glucose levels, and body mass index (BMI). Increases in levels of physical activity. The reduction in glucose levels was large enough to decrease the incidence of a diabetes diagnosis. Ann Intern Med. doi: /m
45
46 Case Report A 45 year old man with a PHx significant for MCD, Obesity, Hyperlipidemia, HTN who despite counseling developed Type 2 DM. BP controlled with ACEI. Total cholesterol 303, TG 1498, Abnormal LFT s, TC/HDL cholesterol 9.2
47 Case Report: 57lb. Weight Loss Total Protein 1.6g/24h Cholesterol 303mg/dl HDL 32.9 Tc/HDL 9.2 LDL CNC TG mg/24h Cholesterol 191mg/dl HDL 49mg/dl Tc/HDL 3.89 LDL 95mg/dl TG 236mg/dl
48 Treatments/Medications If lifestyle changes are inadequate; medication may be necessary: Hypertension (Ace Inhibitors/Angiotensin Receptor Blockers) Dyslipidemia (Statins and fibrates) High Blood Sugar (Metformin) Excessive blood clotting (ASA may be indicated) Ann Intern Med. doi: /m
49 Disease Burden Cardiovascular disease is the leading cause of death in the US CVD risk factors are common in adults Ann Intern Med. doi: /m
50 Disease Burden The Center for Disease Control and Prevention estimates that nearly half of all U.S. adults aged 20 years or older have at least of the following CVD risk factors: Uncontrolled hypertension Elevated low density lipoprotein Current smoking Nearly 70% of U.S. adults are either overweight or obese Ann Intern Med. doi: /m
51 Low carbohydrate vs. Low fat diet 1.Foster GD, et al. A randomized trial of a low-carbohydrate diet for obesity. New England Journal of Medicine, Details: 63 individuals were randomized to either a low-fat diet group, or a low-carb diet group. The low-fat group was calorie restricted. This study went on for 12 months. Weight Loss: The low-carb group lost more weight, 7.3% of total body weight, compared to the low-fat group, which lost 4.5%. The difference was statistically significant at 3 and 6 months, but not 12 months. Conclusion: There was more weight loss in the low-carb group, significant at 3 and 6 months, but not 12. The low-carb group had greater improvements in blood triglycerides and HDL, but other biomarkers were similar between groups. authoritynutrition.com
52 Low carbohydrate vs. Low fat diet 2. Samaha FF, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. New England Journal of Medicine, Details: 132 individuals with severe obesity (mean BMI of 43) were randomized to either a low-fat or a low-carb diet. Many of the subjects had metabolic syndrome or type II diabetes. The low-fat dieters were calorie restricted. Study duration was 6 months. Weight Loss: The low-carb group lost an average of 5.8 kg (12.8 lbs) while the low-fat group lost only 1.9 kg (4.2 lbs). The difference was statistically significant. authoritynutrition.com
53 Low carbohydrate vs. Low carbohydrate diet Conclusion: The low-carb group lost significantly more weight (about 3 times as much). There was also a statistically significant difference in several biomarkers: Triglycerides went down by 38 mg/dl in the LC group, compared to 7 mg/dl in the LF group. Insulin sensitivity improved on LC, got slightly worse on LF. Fasting blood glucose levels went down by 26 mg/dl in the LC group, only 5 mg/dl in the LF group. Insulin levels went down by 27% in the LC group, but increased slightly in the LF group. Overall, the low-carb diet had significantly more beneficial effects on weight and key biomarkers in this group of severely obese individuals. authoritynutrition.com
54 Low carbohydrate vs. Low fat diet 8. Meckling KA, et al. Comparison of a low-fat diet to a lowcarbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. The Journal of Clinical Endocrinology & Metabolism, Details: 40 overweight individuals were randomized to a low-carb and a low-fat diet for 10 weeks. The calories were matched between groups. Weight Loss: The low-carb group lost 7.0 kg (15.4 lbs) and the low-fat group lost 6.8 kg (14.9 lbs). The difference was not statistically significant. authoritynutrition.com
55 Low carbohydrate vs. Low fat diet Conclusion: Both groups lost a similar amount of weight. A few other notable differences in biomarkers: Blood pressure decreased in both groups, both systolic and diastolic. Total and LDL cholesterol decreased in the LF group only. Triglycerides decreased in both groups. HDL cholesterol went up in the LC group, but decreased in the LF group. Blood sugar went down in both groups, but only the LC group had decreases in insulin levels, indicating improved insulin sensitivity. authoritynutrition.com
56 Low carbohydrate vs. Low Carbohydrate diet 19. Volek JS, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids, Details: 40 subjects with elevated risk factors for cardiovascular disease were randomized to a low-carb or a low-fat diet for 12 weeks. Both groups were calorie restricted. Weight Loss: The low-carb group lost 10.1 kg (22.3), while the low-fat group lost 5.2 kg (11.5 lbs). authoritynutrition.com
57 Low carbohydrate vs. Low fat diet Conclusion: The low-carb group lost almost twice the amount of weight as the low-fat group, despite eating the same amount of calories. This study is particularly interesting because it matched calories between groups and measured so-called advanced lipid markers. Several things are worth noting: Triglycerides went down by 107 mg/dl on LC, but 36 mg/dl on the LF diet. HDL cholesterol increased by 4 mg/dl on LC, but went down by 1 mg/dl on LF. Apolipoprotein B went down by 11 points on LC, but only 2 points on LF. LDL size increased on LC, but stayed the same on LF. On the LC diet, the LDL particles partly shifted from small to large (good), while they partly shifted from large to small on LF (bad). authoritynutrition.com
58 Case Report Mrs. D. is a 46 year old woman with a PMH significant for Type 2 Diabetes Mellitus, Hypertension, Dyslipidemia, microalbuminuria, and morbid obesity who was seen in the clinic for weight loss management. BP was 126/80, BMI 54.3kg/m2, : HbA1C : TC 163, LDL 89, HDL 56, TG : weight 356 lbs After weight loss of 60lbs, 70/30 insulin requirement has dropped. From 70/ units bid to 30 units bid : HbA1C has likewise dropped to 6.4
59 Physical Activity
60 Figure 1. A, Joint associations of waist circumference and physical activity with CHD, the Nurses Health Study 1986 to *Adjusted for age (<50, 50 to 54, 55 to 59, 60 to 64, 65), parental history of CHD, postmenopausal status and hormone use (never-use, past, current), physical activity (5 categories), aspirin use (<1, 1 to 2, 3 to 6, 7 to 14, 15+/wk), BMI (<25, 25 to 29.9, 30 kg/m2), and alcohol consumption (0, 0.1 to 4.9, 5 to 14.9, 15 g/d). Li T Y et al. Circulation. 2006;113: Copyright American Heart Association, Inc. All rights reserved.
61 Figure 2. Joint associations of WHR and BMI and CHD, the Nurses Health Study 1986 to *Adjusted for age (<50, 50 to 54, 55 to 59, 60 to 64, 65), parental history of CHD, postmenopausal status and hormone use (never-use, past, current), physical activity (5 categories), aspirin use (<1, 1 to 2, 3 to 6, 7 to 14, 15+/wk), and alcohol consumption (0, 0.1 to 4.9, 5 to 14.9, 15 g/d). Li T Y et al. Circulation. 2006;113: Copyright American Heart Association, Inc. All rights reserved.
62 Goals of Therapy Prevent risk of heart disease Prevent Type 2 Diabetes Mellitus Manage risk factors that can be controlled (weight and sedentary lifestyle) and smoking Ann Intern Med. doi: /m
63 Prevention and Delay of Metabolic Syndrome Regular follow up with the primary care physician A lifelong commitment to a healthy lifestyle (eating habits and exercise) Long-term effort Because of the rise in the prevalence of obesity, Metabolic Syndrome may overtake smoking as the leading cause of Coronary Heart Disease. Ann Intern Med. doi: /m
64 Summary Onset of Type 2 DM can be delayed. The results have been replicated in Finland and China. Assess CVD risks in each patient Managing each cardiac risk factor with ILS interventions and the appropriate medications can reduce CVD morbidity and mortality.
65 Thank you.
66 Pathophysiology Adipose tissue is an endocrine organ. It liberates excess FFA, AT II and adipokines The rise of FFA in the blood inhibit uptake of glucose by muscle. Excess FFA + AT II damage the pancreas (Lipotoxicity) Pancreas increases insulin but not enough to counter the rise of blood sugar, therefore; both insulin and blood sugar rise. Opie L H Circulation. 2007;115:e32-e35
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationAn Interview with Gerald Reaven: Syndrome X : The Risks of Insulin Resistance
An Interview with Gerald Reaven: Syndrome X : The Risks of Insulin Resistance Gerald Reaven, M.D., is Professor Emeritus (Active) of Medicine at Stanford University. He has served as director of the Division
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationCardiovascular Disease Risk Factors
Cardiovascular Disease Risk Factors Risk factors are traits and life-style habits that increase a person's chances of having coronary artery and vascular disease. Some risk factors cannot be changed or
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationThe National Cholesterol Education Program s Adult
NHLBI/AHA Conference Proceedings Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationDiabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationDIABETES AND INSULIN RESISTANCE DIABETES PREVALANCE
DIABETES AND INSULIN RESISTANCE KARI KOHRS RD LDN CDE UICMC NUTRITION & WELLNESS CENTER DIABETES PREVALANCE Third leading cause of death-- United States 18 million diagnosed Growing at the rate of 3 new
More informationDIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE
DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: Robert B. Baron MD MS Professor and
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationA Calorie is a Calorie Or is It? 6 th Biennial Childhood Obesity Conference, June 30, 2011
A Calorie is a Calorie Or is It? 6 th Biennial Childhood Obesity Conference, June 30, 2011 Jeff S. Volek, Ph.D., R.D. Human Performance Laboratory Department of Kinesiology University of Connecticut Storrs,
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationDo You Know the Health Risks of Being Overweight?
Do You Know the Health Risks of Being Overweight? U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH WIN Weight-control Information Network What are the risks to my health from
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationPrimary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
More informationDietary Composition for Weight Loss and Weight Loss Maintenance
Dietary Composition for Weight Loss and Weight Loss Maintenance Bridget M. Hron, MD Instructor in Pediatrics, Harvard Medical School Staff Physician in Gastroenterology & Nutrition and New Balance Foundation
More informationWHAT DOES DYSMETABOLIC SYNDROME MEAN?
! WHAT DOES DYSMETABOLIC SYNDROME MEAN? Dysmetabolic syndrome (also referred to as syndrome X, insulin resistance syndrome, and metabolic syndrome ) is a condition in which a group of risk factors for
More informationDiabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
More informationTriglycerides: Frequently Asked Questions
Triglycerides: Frequently Asked Questions Why are triglycerides important? The amount of triglycerides (or blood fats) in blood are one important barometer of metabolic health; high levels are associated
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationMetabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement
CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationOverview and update of modern type 2 Diabetes philosophy and management. Dr Steve Stanaway Consultant Endocrinologist BCU
Overview and update of modern type 2 Diabetes philosophy and management Dr Steve Stanaway Consultant Endocrinologist BCU Diabetes economics 2009: 2.6M adults with DM in UK (90% type 2) 2025: est. > 4M
More informationDiabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
More informationTHE THIRD REPORT OF THE EXpert
SPECIAL COMMUNICATION Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationInsulin Resistance and PCOS: A not uncommon reproductive disorder
Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses
More informationDIABETES YOUR GUIDE TO
YOUR GUIDE TO DIABETES b What is diabetes? b Type 2 diabetes prevention b Prevention checklist b Living with diabetes b Complications b Terms to know b Resources To promote and protect the health of Canadians
More informationNational Lipid Association 2014 Scientific Sessions, Orlando, FL
National Lipid Association 2014 Scientific Sessions, Orlando, FL Lori Alexander, MSHS, RD, CCRC, CLS, FNLA Site Director St Johns Center for Clinical Research Ponte Vedra, FL Financial Disclosures None
More informationWHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES. Living your life as normal as possible
WHAT IS DIABETES MELLITUS? CAUSES AND CONSEQUENCES DEDBT01954 Lilly Deutschland GmbH Werner-Reimers-Straße 2-4 61352 Bad Homburg Living your life as normal as possible www.lilly-pharma.de www.lilly-diabetes.de
More informationType 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System
Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment Bruce Latham, M.D. Endocrine Specialists Greenville Health System Objectives for this presentation - Understand the thrifty genotype
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationDiabetes and Hypertension Care For Adults in Primary Care Settings
and Hypertension Care For Adults in Primary Care Settings What is Type 2? The carbohydrates including sugar and starch which we take become glucose after digestion. It will then be absorbed by the small
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationTechnology Assessment
Technology Assessment Lifestyle Interventions for Four Conditions: Type 2 Diabetes, Metabolic Syndrome, Breast Cancer, and Prostate Cancer Technology Assessment Program Prepared for: Agency for Healthcare
More informationSedentarity and Exercise in the Canadian Population. Angelo Tremblay Division of kinesiology
Sedentarity and Exercise in the Canadian Population Angelo Tremblay Division of kinesiology Disclosure of Potential Conflicts of Interest Évolution de la pratique d activité physique des adultes canadiens
More informationEffects of macronutrients on insulin resistance and insulin requirements
Effects of macronutrients on insulin resistance and insulin requirements Dr Duane Mellor RD Assistant Professor in Dietetics, The University of Nottingham, UK Outline of Discussion Issues of determining
More informationStroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012
Faculty Prevention Sharon Ewer, RN, BSN, CNRN Stroke Program Coordinator Baptist Health Montgomery, Alabama Satellite Conference and Live Webcast Monday, May 21, 2012 2:00 4:00 p.m. Central Time Produced
More informationADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines for the monitoring of antihypertensive therapy in adult patients and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident.
More informationPlasma Testosterone Level in Male Patients with Metabolic Syndrome
Med. J. Cairo Univ., Vol. 77, No. 1, June: 351-357, 2009 www.medicaljournalofcairouniversity.com Plasma Testosterone Level in Male Patients with Metabolic Syndrome NASHWA EL-SARRAF, M.D. and AMR EL-HADIDY,
More informationNutrition Therapy in Diabetes Mellitus. Dorothy Debrah Diabetes Specialist Dietitian University Hospital, Llandough. Wales, UK February 2012
Nutrition Therapy in Diabetes Mellitus. Dorothy Debrah Diabetes Specialist Dietitian University Hospital, Llandough. Wales, UK February 2012 University Hospital Llandough DIABETES MELLITUS. Definition:
More informationDiabetes is a. A case for prevention of type 2 diabetes mellitus
A case for prevention of type 2 diabetes mellitus Joseph Cook, DO Diabetes is a disease that has reached epidemic proportions in the United States and around the world. This is troubling because, as bad
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationAn Overview and Guide to Healthy Living with Type 2 Diabetes
MEETING YOUR GOALS An Overview and Guide to Healthy Living with Type 2 Diabetes MEETING YOUR GOALS This brochure was designed to help you understand the health goals to live a healthy lifestyle with type
More informationYOUR LAST DIET IDEAL PROTEIN
YOUR LAST DIET IDEAL PROTEIN OBJECTIVES Explain the science and history that supports the Ideal Protein Diet method. Describe the risks and benefits of diet participation. Give you the details of what
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationDiabetic Nephropathy
Diabetic Nephropathy Kidney disease is common in people affected by diabetes mellitus Definition Urinary albumin excretion of more than 300mg in a 24 hour collection or macroalbuminuria Abnormal renal
More informationFamily History and Diabetes. Practical Genomics for the Public Health Professional
Family History and Diabetes Practical Genomics for the Public Health Professional Outline Overview of Type 2 Diabetes/Gestational Diabetes Familial/Genetic Nature of Diabetes Interaction of Genes and Environment
More information3.5% 3.0% 3.0% 2.4% Prevalence 2.0% 1.5% 1.0% 0.5% 0.0%
S What is Heart Failure? 1,2,3 Heart failure, sometimes called congestive heart failure, develops over many years and results when the heart muscle struggles to supply the required oxygen-rich blood to
More informationComplicanze del diabete nel bambino e nell adolescente
Clinica Pediatrica Università di Chieti Complicanze del diabete nel bambino e nell adolescente Franco Chiarelli XVII Congresso Nazionale SIPPS Parma, 25 Novembre 2005 Type 1 diabetes in childhood: Only
More informationHigh Blood pressure and chronic kidney disease
High Blood pressure and chronic kidney disease For People with CKD Stages 1 4 www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney
More informationMenopause. Weight Loss. A Special Report on Weight Gain During Menopause. contact us. FROM THE DESK OF: Carolyn J. Cederquist, M.D. Dr.
Weight Loss & A Special Report on Weight Gain During Menopause Menopause FROM THE DESK OF: Carolyn J. Cederquist, M.D. Dr. Cederquist Caroline J. Cederquist, M.D., has appeared as a weight-management expert
More informationDIABETES MELLITUS. By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria
DIABETES MELLITUS By Tracey Steenkamp Biokineticist at the Institute for Sport Research, University of Pretoria What is Diabetes Diabetes Mellitus (commonly referred to as diabetes ) is a chronic medical
More informationMen Sexual Dysfunction Associated with Obesity and Metabolic Syndrome
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationCholesterol and Triglycerides What You Should Know
Cholesterol and Triglycerides What You Should Know Michael T. McDermott MD Professor of Medicine Endocrinology Practice Director Division of Endocrinology, Metabolism and Diabetes University of Colorado
More informationAdult Weight Management Training Summary
Adult Weight Management Training Summary The Commission on Dietetic Registration, the credentialing agency for the Academy of Nutrition and Dietetics Marilyn Holmes, MS, RDN, LDN About This Presentation
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationPractice Guidelines for the
1 Treatment goals: Practice Guidelines for the The goal of treatment is to keep blood sugar at normal or near-normal levels. This reduces the risk of complications associated with diabetes. A normal fasting
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationDiabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
More informationMetabolic syndrome a new world-wide definition. A Consensus Statement from the International Diabetes Federation
Metabolic syndrome a new world-wide definition. Oxford, DME Diabetic 0742-3071 Blackwell 23 Special Report report UK Medicine Publishing, syndrome K. Ltd 2006 G. M. M. Alberti al. A Consensus Statement
More informationKaren Kovach M.S, R.D Chief Scientific Officer Weight Watchers International Inc.
Waking up to real solutions to Chronic Disease: Tackling obesity can reduce the burden of chronic disease and deliver substantial cost savings to struggling European healthcare systems Karen Kovach M.S,
More informationYOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels
YOUR GUIDE TO Managing and Understanding Your Cholesterol Levels Our goal at the Mercy Health Heart Institute is to help you be well. Our experienced team includes cardiologists, cardiovascular surgeons,
More informationDefinition of Diabetes Mellitus
Definition of Diabetes Mellitus Diabetes mellitus consists of a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. U.S. Diabetes
More information